Recursion, Takeda enter rare disease discovery partnership

Recursion Pharmaceuticals Inc. (Salt Lake City, Utah) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will collaborate to discover preclinical rare disease candidates for Takeda's TAK-celerator pipeline.

Recursion will receive an undisclosed upfront payment and is eligible for more than $90 million in milestones, plus royalties. ...